NO933000L - Anvendelse av C1-inaktivator for fremstilling av et legemiddel for profylakse og behandling av bestemte sykdommer - Google Patents
Anvendelse av C1-inaktivator for fremstilling av et legemiddel for profylakse og behandling av bestemte sykdommerInfo
- Publication number
- NO933000L NO933000L NO933000A NO933000A NO933000L NO 933000 L NO933000 L NO 933000L NO 933000 A NO933000 A NO 933000A NO 933000 A NO933000 A NO 933000A NO 933000 L NO933000 L NO 933000L
- Authority
- NO
- Norway
- Prior art keywords
- inactivator
- prophylaxis
- drug
- manufacture
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Physiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4227762A DE4227762A1 (de) | 1992-08-24 | 1992-08-24 | Verwendung eines Kallikrein-Inhibitors zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie bestimmter Krankheiten |
Publications (2)
Publication Number | Publication Date |
---|---|
NO933000D0 NO933000D0 (no) | 1993-08-23 |
NO933000L true NO933000L (no) | 1994-02-25 |
Family
ID=6466096
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO933000A NO933000L (no) | 1992-08-24 | 1993-08-23 | Anvendelse av C1-inaktivator for fremstilling av et legemiddel for profylakse og behandling av bestemte sykdommer |
Country Status (9)
Country | Link |
---|---|
US (1) | US5939389A (fr) |
EP (1) | EP0586909A3 (fr) |
JP (1) | JPH06157343A (fr) |
KR (1) | KR100290753B1 (fr) |
AU (1) | AU671287B2 (fr) |
CA (1) | CA2104636C (fr) |
DE (2) | DE4227762A1 (fr) |
IL (1) | IL106776A0 (fr) |
NO (1) | NO933000L (fr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4227762A1 (de) * | 1992-08-24 | 1994-03-03 | Behringwerke Ag | Verwendung eines Kallikrein-Inhibitors zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie bestimmter Krankheiten |
WO1997022347A1 (fr) * | 1995-12-18 | 1997-06-26 | Stichting Sanquin Bloedvoorziening | Potentialisation des proprietes d'inhibition du complement et de la coagulation d'un inhibiteur de c1 |
DE19827750C1 (de) | 1998-06-22 | 1999-07-29 | Centeon Pharma Gmbh | Verfahren zum Abtrennen von HIV aus einer Flüssigkeit |
US20040152635A1 (en) * | 1998-06-22 | 2004-08-05 | Albrecht Groner | Modified C1 esterase inhibitor for blocking the infectiousness of HIV |
AU2006203549B2 (en) * | 2000-01-31 | 2008-10-09 | Pharming Intellectual Property B.V. | C1 inhibitor produced in the milk of transgenic mammals |
US7067713B2 (en) | 2000-01-31 | 2006-06-27 | Pharming Intellectual Property B.V. | C1 Inhibitor produced in the milk of transgenic non-human mammals |
EP1252184B1 (fr) * | 2000-01-31 | 2008-01-02 | Pharming Intellectual Property B.V. | Inhibiteur de c1 human produit dans du lait de mammiferes transgeniques |
PL1626736T3 (pl) | 2003-05-16 | 2021-05-04 | Pharming Intellectual Property B.V. | Inhibitor c1 o krótkim okresie półtrwania do leczenia przejściowego |
CA3154415A1 (fr) | 2006-10-10 | 2008-04-17 | Regenesance B.V. | Oligonucleotide antisens destine a l'utilisation dans la facilitation de la regeneration axonale |
DK2758076T3 (en) | 2011-09-24 | 2019-04-01 | Csl Behring Gmbh | COMBINATION THERAPY USING IMMUNOGLOBULIN AND C1 INHIBITOR |
WO2013093027A1 (fr) | 2011-12-22 | 2013-06-27 | Csl Behring Gmbh | Utilisation d'un c1-inhibiteur destiné au traitement d'un œdème secondaire du système nerveux central |
US10441631B2 (en) | 2013-02-28 | 2019-10-15 | Csl Behring Gmbh | Therapeutic agent for amniotic fluid embolism |
AU2014224599B2 (en) | 2013-03-08 | 2018-11-08 | Csl Behring Gmbh | Treatment and prevention of remote ischemia-reperfusion injury |
JP2017501968A (ja) | 2013-06-28 | 2017-01-19 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 第xii因子インヒビターおよびc1−インヒビターを使用する組合せ療法 |
EP3302529A4 (fr) | 2015-06-03 | 2019-02-06 | The Children's Hospital Medical Center | Compositions et procédés pour le traitement de l'atrésie des voies biliaires néonatale |
US20190175683A1 (en) | 2016-08-05 | 2019-06-13 | Csl Behring Gmbh | Pharmaceutical formulations of c1 esterase inhibitor |
WO2018037046A1 (fr) | 2016-08-23 | 2018-03-01 | Csl Behring Gmbh | Procédé de prévention d'attaques aiguës d'œdème de quincke héréditaire associées à une déficience en inhibiteur de c1 estérase |
EP3681517B1 (fr) | 2017-09-15 | 2024-05-08 | Cedars-Sinai Medical Center | Inhibiteurs de la c1 estérase pour leur utilisation pour améliorer la fonction des organes chez les patients greffés d'organes |
EP4247416A1 (fr) | 2020-11-20 | 2023-09-27 | CSL Behring GmbH | Méthodes de traitement d?un rejet à médiation par anticorps |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3228502A1 (de) * | 1982-07-30 | 1984-02-02 | Behringwerke Ag, 3550 Marburg | Verfahren zur herstellung des c1-inaktivators und seine verwendung |
US5271931A (en) * | 1988-09-14 | 1993-12-21 | The Scripps Research Institute | Methods for increasing C1 inhibitor concentrations using interferon-gamma and/or interleukin-6 |
US5030578A (en) * | 1989-07-10 | 1991-07-09 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Process for the purification of C1-inhibitor |
EP0512090B2 (fr) * | 1990-10-16 | 2006-11-22 | Sonoran Desert Chemicals LLC | Traitement d'inflammations |
WO1992022320A1 (fr) * | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Variantes de l'inhibiteur c1 et traitement des reactions inflammatoires avec l'inhibiteur c1 |
DE4227735C2 (de) * | 1992-08-21 | 1995-10-12 | Leybold Ag | Anordnung zum berührungslosen Messen der Dicke von Schichten |
DE4227762A1 (de) * | 1992-08-24 | 1994-03-03 | Behringwerke Ag | Verwendung eines Kallikrein-Inhibitors zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie bestimmter Krankheiten |
-
1992
- 1992-08-24 DE DE4227762A patent/DE4227762A1/de not_active Withdrawn
- 1992-08-24 DE DE4244735A patent/DE4244735A1/de not_active Withdrawn
-
1993
- 1993-08-11 EP EP93112844A patent/EP0586909A3/fr not_active Ceased
- 1993-08-23 AU AU44778/93A patent/AU671287B2/en not_active Ceased
- 1993-08-23 CA CA002104636A patent/CA2104636C/fr not_active Expired - Lifetime
- 1993-08-23 JP JP5207334A patent/JPH06157343A/ja active Pending
- 1993-08-23 IL IL106776A patent/IL106776A0/xx unknown
- 1993-08-23 NO NO933000A patent/NO933000L/no not_active Application Discontinuation
- 1993-08-23 KR KR1019930016325A patent/KR100290753B1/ko not_active IP Right Cessation
-
1997
- 1997-05-12 US US08/854,365 patent/US5939389A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
AU4477893A (en) | 1994-03-03 |
CA2104636C (fr) | 2003-11-11 |
US5939389A (en) | 1999-08-17 |
JPH06157343A (ja) | 1994-06-03 |
DE4227762A1 (de) | 1994-03-03 |
AU671287B2 (en) | 1996-08-22 |
DE4244735A1 (de) | 1994-03-31 |
EP0586909A3 (fr) | 1995-04-05 |
CA2104636A1 (fr) | 1994-02-25 |
IL106776A0 (en) | 1993-12-08 |
KR100290753B1 (ko) | 2001-09-17 |
EP0586909A2 (fr) | 1994-03-16 |
KR940003564A (ko) | 1994-03-12 |
NO933000D0 (no) | 1993-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO933000L (no) | Anvendelse av C1-inaktivator for fremstilling av et legemiddel for profylakse og behandling av bestemte sykdommer | |
SE8406538D0 (sv) | Novel derivatives of purine | |
LU90192I2 (fr) | Desirudine et ses sels et dérivés pharmaceutiquement acceptables (revasc) | |
ES2160707T3 (es) | Composiciones que comprenden agentes deteriorantes del adn y p53. | |
ES2036199T3 (es) | Procedimiento de obtencion de un preparado farmaceutico administrable a traves de una membrana corporal. | |
MD1224B2 (en) | Application of nucleoside analogues with 1,3-oxathiolan for treatment of hepatitis B | |
LU92425I2 (fr) | Dichlorure de radium Ra 2232 et ses dérivés pharmaceutiquement acceptables (XOFIGO®) | |
DK0913156T3 (da) | Anvendelse af aktiveret protein C til behandling af hyperkoagulationstilstande i forbindelse med sepsis | |
ATE87214T1 (de) | Verwendung katabolischer enzyme zur herstellung eines medikaments zum bekaempfen der erworbenen immunschwaeche (aids) und deren vorstadien (las, arc). | |
ES8609325A1 (es) | Un procedimiento para preparar derivados de guanina | |
DE69905368D1 (en) | Oxydiertes thymosin beta 4 | |
SE8000435L (sv) | N-bensylimidazoler med selektivt inhiberande verkan pa tromboxansyntetasenzymet jemte farmaceutiska beredningar innehallande sadana n-bensylimidazoler och sett for deras framstellning | |
GR3019514T3 (en) | Pharmaceutical preparation for the treatment of prolonged coagulation time | |
DE3372712D1 (en) | A tube set intended for extracorporeal treatment of blood and similar perishable liquids | |
ES549776A0 (es) | Procedimiento para la preparacion de pirrolo-bencimidazoles | |
HUP9801924A2 (hu) | Nátrium/hidrogén-csere inhibitorokat és szív- és keringési zavarok kezelésére alkalmas hatóanyagokat tartalmazó gyógyszerkészítmény | |
MX9205568A (es) | Composicion farmaceutica que contiene cantidades de 5-amino-1beta-d-ribofuranosil-imidazol-4-carboxamida. | |
Schlossberg | Multiple erythematous nodules as a manifestation of Pseudomonas aeruginosa septicemia | |
FI863565A0 (fi) | Foerfarande foer framstaellning av nya pyrrobenzimidazoler, pyrrolbenzoxazoler och pyrrolbenztiazoler. | |
MC1930A1 (fr) | Produit antiviral | |
MY124071A (en) | Treatment of viral disease in swine | |
GR3006147T3 (fr) | ||
DK162477C (da) | Anvendelse af gonadoliberin eller den gonadoliberin-analoge buserelin til fremstilling af et farmaceutisk praeparat til behandling af klimakterielle besvaerligheder og patologiske tilstande med forhoejet parathormonspejl | |
EP0231425A3 (en) | Use of a solution of alpha-chymotrypsin | |
JO1493B1 (en) | Pharmaceutical combination for treating high blood pressure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |